The Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line ...
New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s ...
After committing $55 billion last year to bolster U.S. manufacturing capabilities, Johnson & Johnson is making changes to its ...
Biopharma companies won’t fully capture the benefits of AI unless they reorganize their R&D units, according to McKinsey.
With the latest layoffs, Novartis expects to let go of around 800 employees by the end of 2028. More than half of the cuts ...
Eli Lilly’s anti-amyloid Alzheimer’s drug is designed to be stopped after patients drop below a certain amyloid level in the ...
An unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, ...
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options. Merck has secured the ...
The FDA last week confirmed that it would suspend the release of complete response letters pending the resolution of a citizen petition from an unnamed pharma company. Nevertheless, 14 new CRLs are ...
Just weeks after Pfizer’s Seagen-acquired antibody-drug conjugate sigvotatug vedotin failed a Phase 3 non-small cell lung cancer study, the big pharma has quietly culled another program being ...
Takeda’s cuts will go the deepest, affecting over 4,700 employees. Layoffs tied to M&A activity include BioNTech letting go of around 800 people at CureVac. The number of biopharmas implementing or ...
Dizal Pharmaceutical’s Zegfrovy is approved in the U.S. for locally advanced or metastatic non-small cell lung cancer. For $600 million upfront, AstraZeneca will gain global rights to advance and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results